Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Seminars in Immunopathology
Erschienen in: Seminars in Immunopathology 2/2011

01.03.2011 | Review

Lung transplantation: infection, inflammation, and the microbiome

verfasst von: Takeshi Nakajima, Vyachesav Palchevsky, David L. Perkins, John A. Belperio, Patricia W. Finn

Erschienen in: Seminars in Immunopathology | Ausgabe 2/2011

Einloggen, um Zugang zu erhalten

Abstract

Lung transplantation is the only therapeutic option for patients with end-stage pulmonary disorders. Despite the improvements in surgical techniques and immunosuppressive therapy, allograft function and long-term survival are limited by the development of chronic lung transplant rejection. In this review, we focus on bronchiolitis obliterans syndrome (BOS) which is the major manifestation of chronic lung allograft rejection. We specifically review the effect of infection, a risk factor for BOS, cytokines/chemokines in the pathogenesis of BOS, and the potential link between the allograft microbiome and immune responses that may mediate the development of BOS. Understanding the allograft microbiome and how it relates to the pathologic mechanisms of BOS may suggest targeted therapies to improve long-term survival post-lung transplantation.
Literatur
1.
Christie JD, Edwards LB, Kucheryavaya AY, Aurora P, Dobbels F, Kirk R, Rahmel AO, Stehlik J, Hertz MI (2010) The Registry of the International Society for Heart and Lung Transplantation: twenty-seventh official adult lung and heart–lung transplant report—2010. J Heart Lung Transplant 29(10):1104–1118PubMed
2.
Verleden GM (2001) Chronic allograft rejection (obliterative bronchiolitis). Semin Respir Crit Care Med 22(5):551–558PubMed
3.
Verleden GM, Dupont LJ, Van Raemdonck DE (2005) Is it bronchiolitis obliterans syndrome or is it chronic rejection: a reappraisal? Eur Respir J 25(2):221–224PubMed
4.
Vanaudenaerde BM, Meyts I, Vos R, Geudens N, De Wever W, Verbeken EK, Van Raemdonck DE, Dupont LJ, Verleden GM (2008) A dichotomy in bronchiolitis obliterans syndrome after lung transplantation revealed by azithromycin therapy. Eur Respir J 32(4):832–843. doi:10.​1183/​09031936.​00134307 PubMed
5.
Estenne M, Hertz MI (2002) Bronchiolitis obliterans after human lung transplantation. Am J Respir Crit Care Med 166(4):440–444PubMed
6.
Estenne M, Maurer JR, Boehler A, Egan JJ, Frost A, Hertz M, Mallory GB, Snell GI, Yousem S (2002) Bronchiolitis obliterans syndrome 2001: an update of the diagnostic criteria. J Heart Lung Transplant 21(3):297–310PubMed
7.
Knoop C, Estenne M (2006) Acute and chronic rejection after lung transplantation. Semin Respir Crit Care Med 27(5):521–533PubMed
8.
Belperio JA, Lake K, Tazelaar H, Keane MP, Strieter RM, Lynch JP 3rd (2003) Bronchiolitis obliterans syndrome complicating lung or heart–lung transplantation. Semin Respir Crit Care Med 24(5):499–530. doi:10.​1055/​s-2004-815601 PubMed
9.
Stewart S, Fishbein MC, Snell GI, Berry GJ, Boehler A, Burke MM, Glanville A, Gould FK, Magro C, Marboe CC, McNeil KD, Reed EF, Reinsmoen NL, Scott JP, Studer SM, Tazelaar HD, Wallwork JL, Westall G, Zamora MR, Zeevi A, Yousem SA (2007) Revision of the 1996 working formulation for the standardization of nomenclature in the diagnosis of lung rejection. J Heart Lung Transplant 26(12):1229–1242PubMed
10.
Glanville AR, Aboyoun CL, Havryk A, Plit M, Rainer S, Malouf MA (2008) Severity of lymphocytic bronchiolitis predicts long term outcome after lung transplantation. Am J Respir Crit Care Med 177:1033–1040PubMed
11.
Husain AN, Siddiqui MT, Holmes EW, Chandrasekhar AJ, McCabe M, Radvany R, Garrity ER (1999) Analysis of risk factors for the development of bronchiolitis obliterans syndrome. Am J Respir Crit Care Med 159(3):829–833PubMed
12.
Hachem RR, Khalifah AP, Chakinala MM, Yusen RD, Aloush AA, Mohanakumar T, Patterson GA, Trulock EP, Walter MJ (2005) The significance of a single episode of minimal acute rejection after lung transplantation. Transplantation 80(10):1406–1413PubMed
13.
Hopkins PM, Aboyoun CL, Chhajed PN, Malouf MA, Plit ML, Rainer SP, Glanville AR (2004) Association of minimal rejection in lung transplant recipients with obliterative bronchiolitis. Am J Respir Crit Care Med 170(9):1022–1026PubMed
14.
Burton CM, Iversen M, Scheike T, Carlsen J, Andersen CB (2008) Is lymphocytic bronchiolitis a marker of acute rejection? An analysis of 2,697 transbronchial biopsies after lung transplantation. J Heart Lung Transplant 27(10):1128–1134. doi:10.​1016/​j.​healun.​2008.​06.​014 PubMed
15.
Weigt SS, Wallace WD, Derhovanessian A, Saggar R, Lynch JP, Belperio JA (2010) Chronic allograft rejection: epidemiology, diagnosis, pathogenesis, and treatment. Semin Respir Crit Care Med 31(2):189–207. doi:10.​1055/​s-0030-1249116 PubMed
16.
17.
Gordon S (2003) Alternative activation of macrophages. Nat Rev Immunol 3(1):23–35PubMed
18.
Zingoni A, Sornasse T, Cocks BG, Tanaka Y, Santoni A, Lanier LL (2005) NK cell regulation of T cell-mediated responses. Mol Immunol 42(4):451–454PubMed
19.
Mosmann TR, Sad S (1996) The expanding universe of T-cell subsets: Th1, Th2 and more. Immunol Today 17(3):138–146PubMed
20.
Mantovani A, Allavena P, Sica A (2004) Tumour-associated macrophages as a prototypic type II polarised phagocyte population: role in tumour progression. Eur J Cancer 40(11):1660–1667PubMed
21.
Zhai Y, Kupiec-Weglinski JW (1999) What is the role of regulatory T cells in transplantation tolerance? Curr Opin Immunol 11(5):497–503PubMed
22.
Mosmann TR, Cherwinski H, Bond MW, Giedlin MA, Coffman RL (1986) Two types of murine helper T cell clone I. Definition according to profiles of lymphokine activities and secreted proteins. J Immunol 136(7):2348–2357PubMed
23.
Zlotnik A, Yoshie O (2000) Chemokines: a new classification system and their role in immunity. Immunity 12(2):121–127PubMed
24.
Fontenot JD, Gavin MA, Rudensky AY (2003) Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol 4(4):330–336PubMed
25.
Speich R, van der Bij W (2001) Epidemiology and management of infections after lung transplantation. Clin Infect Dis 33(Suppl 1):S58–S65. doi:10.​1086/​320906 PubMed
26.
Mulligan MS (2001) Endoscopic management of airway complications after lung transplantation. Chest Surg Clin N Am 11(4):907–915PubMed
27.
Kshettry VR, Kroshus TJ, Hertz MI, Hunter DW, Shumway SJ, Bolman RM 3rd (1997) Early and late airway complications after lung transplantation: incidence and management. Ann Thorac Surg 63(6):1576–1583PubMed
28.
Yankaskas JR, Mallory GB Jr (1998) Lung transplantation in cystic fibrosis: consensus conference statement. Chest 113(1):217–226PubMed
29.
Flume PA, Egan TM, Paradowski LJ, Detterbeck FC, Thompson JT, Yankaskas JR (1994) Infectious complications of lung transplantation. Impact of cystic fibrosis. Am J Respir Crit Care Med 149(6):1601–1607PubMed
30.
de Leval MR, Smyth R, Whitehead B, Scott JP, Elliott MJ, Sharples L, Caine N, Helms P, Martin IR, Higenbottam T (1991) Heart and lung transplantation for terminal cystic fibrosis. A 4 1/2-year experience. J Thorac Cardiovasc Surg 101(4):633–641, discussion 641–632PubMed
31.
Snell GI, de Hoyos A, Krajden M, Winton T, Maurer JR (1993) Pseudomonas cepacia in lung transplant recipients with cystic fibrosis. Chest 103(2):466–471PubMed
32.
Sun L, Jiang RZ, Steinbach S, Holmes A, Campanelli C, Forstner J, Sajjan U, Tan Y, Riley M, Goldstein R (1995) The emergence of a highly transmissible lineage of cbl+ Pseudomonas (Burkholderia) cepacia causing CF centre epidemics in North America and Britain. Nat Med 1(7):661–666PubMed
33.
Hadjiliadis D, Sporn TA, Perfect JR, Tapson VF, Davis RD, Palmer SM (2002) Outcome of lung transplantation in patients with mycetomas. Chest 121(1):128–134PubMed
34.
Olivier KN, Weber DJ, Lee JH, Handler A, Tudor G, Molina PL, Tomashefski J, Knowles MR (2003) Nontuberculous mycobacteria. II: nested-cohort study of impact on cystic fibrosis lung disease. Am J Respir Crit Care Med 167(6):835–840PubMed
35.
Fishman JA, Rubin RH (1998) Infection in organ-transplant recipients. N Engl J Med 338(24):1741–1751PubMed
36.
Kuo CJ, Chung J, Fiorentino DF, Flanagan WM, Blenis J, Crabtree GR (1992) Rapamycin selectively inhibits interleukin-2 activation of p70 S6 kinase. Nature 358(6381):70–73PubMed
37.
Price DJ, Grove JR, Calvo V, Avruch J, Bierer BE (1992) Rapamycin-induced inhibition of the 70-kilodalton S6 protein kinase. Science 257(5072):973–977PubMed
38.
King-Biggs MB, Dunitz JM, Park SJ, Kay Savik S, Hertz MI (2003) Airway anastomotic dehiscence associated with use of sirolimus immediately after lung transplantation. Transplantation 75(9):1437–1443PubMed
39.
Snell GI, Valentine VG, Vitulo P, Glanville AR, McGiffin DC, Loyd JE, Roman A, Aris R, Sole A, Hmissi A, Pirron U (2006) Everolimus versus azathioprine in maintenance lung transplant recipients: an international, randomized, double-blind clinical trial. Am J Transplant 6(1):169–177PubMed
40.
Battaglia M, Stabilini A, Migliavacca B, Horejs-Hoeck J, Kaupper T, Roncarolo MG (2006) Rapamycin promotes expansion of functional CD4+CD25+FOXP3+ regulatory T cells of both healthy subjects and type 1 diabetic patients. J Immunol 177(12):8338–8347PubMed
41.
Segundo DS, Ruiz JC, Izquierdo M, Fernandez-Fresnedo G, Gomez-Alamillo C, Merino R, Benito MJ, Cacho E, Rodrigo E, Palomar R, Lopez-Hoyos M, Arias M (2006) Calcineurin inhibitors, but not rapamycin, reduce percentages of CD4+CD25+FOXP3+ regulatory T cells in renal transplant recipients. Transplantation 82(4):550–557PubMed
42.
Aguilar-Guisado M, Givalda J, Ussetti P, Ramos A, Morales P, Blanes M, Bou G, de la Torre-Cisneros J, Roman A, Borro JM, Lama R, Cisneros JM (2007) Pneumonia after lung transplantation in the RESITRA Cohort: a multicenter prospective study. Am J Transplant 7(8):1989–1996. doi:10.​1111/​j.​1600-6143.​2007.​01882.​x PubMed
43.
Valentine VG, Bonvillain RW, Gupta MR, Lombard GA, LaPlace SG, Dhillon GS, Wang G (2008) Infections in lung allograft recipients: ganciclovir era. J Heart Lung Transplant 27(5):528–535PubMed
44.
Sharples LD, McNeil K, Stewart S, Wallwork J (2002) Risk factors for bronchiolitis obliterans: a systematic review of recent publications. J Heart Lung Transplant 21(2):271–281PubMed
45.
Mattner F, Fischer S, Weissbrodt H, Chaberny IF, Sohr D, Gottlieb J, Welte T, Henke-Gendo C, Gastmeier P, Strueber M (2007) Post-operative nosocomial infections after lung and heart transplantation. J Heart Lung Transplant 26(3):241–249. doi:10.​1016/​j.​healun.​2006.​12.​009 PubMed
46.
47.
Bonvillain RW, Valentine VG, Lombard G, LaPlace S, Dhillon G, Wang G (2007) Post-operative infections in cystic fibrosis and non-cystic fibrosis patients after lung transplantation. J Heart Lung Transplant 26(9):890–897. doi:10.​1016/​j.​healun.​2007.​07.​002 PubMed
48.
Gottlieb J, Mattner F, Weissbrodt H, Dierich M, Fuehner T, Strueber M, Simon A, Welte T (2009) Impact of graft colonization with Gram-negative bacteria after lung transplantation on the development of bronchiolitis obliterans syndrome in recipients with cystic fibrosis. Respir Med 103(5):743–749. doi:10.​1016/​j.​rmed.​2008.​11.​015 PubMed
49.
Botha P, Archer L, Anderson RL, Lordan J, Dark JH, Corris PA, Gould K, Fisher AJ (2008) Pseudomonas aeruginosa colonization of the allograft after lung transplantation and the risk of bronchiolitis obliterans syndrome. Transplantation 85(5):771–774PubMed
50.
Vos R, Vanaudenaerde BM, Geudens N, Dupont LJ, Van Raemdonck DE, Verleden GM (2008) Pseudomonal airway colonisation: risk factor for bronchiolitis obliterans syndrome after lung transplantation? Eur Respir J 31(5):1037–1045PubMed
51.
Chaparro C, Maurer J, Gutierrez C, Krajden M, Chan C, Winton T, Keshavjee S, Scavuzzo M, Tullis E, Hutcheon M, Kesten S (2001) Infection with Burkholderia cepacia in cystic fibrosis: outcome following lung transplantation. Am J Respir Crit Care Med 163(1):43–48PubMed
52.
Meachery G, De Soyza A, Nicholson A, Parry G, Hasan A, Tocewicz K, Pillay T, Clark S, Lordan JL, Schueler S, Fisher AJ, Dark JH, Gould FK, Corris PA (2008) Outcomes of lung transplantation for cystic fibrosis in a large UK cohort. Thorax 63(8):725–731. doi:10.​1136/​thx.​2007.​092056 PubMed
53.
Boussaud V, Guillemain R, Grenet D, Coley N, Souilamas R, Bonnette P, Stern M (2008) Clinical outcome following lung transplantation in patients with cystic fibrosis colonised with Burkholderia cepacia complex: results from two French centres. Thorax 63(8):732–737. doi:10.​1136/​thx.​2007.​089458 PubMed
54.
Alexander BD, Petzold EW, Reller LB, Palmer SM, Davis RD, Woods CW, Lipuma JJ (2008) Survival after lung transplantation of cystic fibrosis patients infected with Burkholderia cepacia complex. Am J Transplant 8(5):1025–1030. doi:10.​1111/​j.​1600-6143.​2008.​02186.​x PubMed
55.
56.
Kesten S, Chaparro C (1999) Mycobacterial infections in lung transplant recipients. Chest 115(3):741–745PubMed
57.
Malouf MA, Glanville AR (1999) The spectrum of mycobacterial infection after lung transplantation. Am J Respir Crit Care Med 160(5 Pt 1):1611–1616PubMed
58.
Kotloff RM, Ahya VN, Crawford SW (2004) Pulmonary complications of solid organ and hematopoietic stem cell transplantation. Am J Respir Crit Care Med 170(1):22–48PubMed
59.
Segal BH, Walsh TJ (2006) Current approaches to diagnosis and treatment of invasive aspergillosis. Am J Respir Crit Care Med 173(7):707–717PubMed
60.
Sole A, Morant P, Salavert M, Peman J, Morales P (2005) Aspergillus infections in lung transplant recipients: risk factors and outcome. Clin Microbiol Infect 11(5):359–365PubMed
61.
Marik PE (2006) Fungal infections in solid organ transplantation. Expert Opin Pharmacother 7(3):297–305PubMed
62.
Singh N, Husain S (2003) Aspergillus infections after lung transplantation: clinical differences in type of transplant and implications for management. J Heart Lung Transplant 22(3):258–266PubMed
63.
Alexander BD, Tapson VF (2001) Infectious complications of lung transplantation. Transpl Infect Dis 3(3):128–137PubMed
64.
Weigt SS, Elashoff RM, Huang C, Ardehali A, Gregson AL, Kubak B, Fishbein MC, Saggar R, Keane MP, Lynch JP 3rd, Zisman DA, Ross DJ, Belperio JA (2009) Aspergillus colonization of the lung allograft is a risk factor for bronchiolitis obliterans syndrome. Am J Transplant 9(8):1903–1911. doi:10.​1111/​j.​1600-6143.​2009.​02635.​x PubMed
65.
Cahill BC, Hibbs JR, Savik K, Juni BA, Dosland BM, Edin-Stibbe C, Hertz MI (1997) Aspergillus airway colonization and invasive disease after lung transplantation. Chest 112(5):1160–1164PubMed
66.
Monforte V, Roman A, Gavalda J, Bravo C, Tenorio L, Ferrer A, Maestre J, Morell F (2001) Nebulized amphotericin B prophylaxis for Aspergillus infection in lung transplantation: study of risk factors. J Heart Lung Transplant 20(12):1274–1281PubMed
67.
Paradowski LJ (1997) Saprophytic fungal infections and lung transplantation—revisited. J Heart Lung Transplant 16(5):524–531PubMed
68.
Khalifah AP, Hachem RR, Chakinala MM, Schechtman KB, Patterson GA, Schuster DP, Mohanakumar T, Trulock EP, Walter MJ (2004) Respiratory viral infections are a distinct risk for bronchiolitis obliterans syndrome and death. Am J Respir Crit Care Med 170(2):181–187PubMed
69.
Bharat A, Kuo E, Saini D, Steward N, Hachem R, Trulock EP, Patterson GA, Meyers BF, Mohanakumar T (2010) Respiratory virus-induced dysregulation of T-regulatory cells leads to chronic rejection. Ann Thorac Surg 90(5):1637–1644, discussion 1644PubMed
70.
Zamora MR, Davis RD, Leonard C (2005) Management of cytomegalovirus infection in lung transplant recipients: evidence-based recommendations. Transplantation 80(2):157–163PubMed
71.
Weigt SS, Elashoff RM, Keane MP, Strieter RM, Gomperts BN, Xue YY, Ardehali A, Gregson AL, Kubak B, Fishbein MC, Saggar R, Ross DJ, Lynch JP 3rd, Zisman DA, Belperio JA (2008) Altered levels of CC chemokines during pulmonary CMV predict BOS and mortality post-lung transplantation. Am J Transplant 8:1512–1522PubMed
72.
Bridges ND, Spray TL, Collins MH, Bowles NE, Towbin JA (1998) Adenovirus infection in the lung results in graft failure after lung transplantation. J Thorac Cardiovasc Surg 116(4):617–623PubMed
73.
Palmer SM Jr, Henshaw NG, Howell DN, Miller SE, Davis RD, Tapson VF (1998) Community respiratory viral infection in adult lung transplant recipients. Chest 113(4):944–950PubMed
74.
Simsir A, Greenebaum E, Nuovo G, Schulman LL (1998) Late fatal adenovirus pneumonitis in a lung transplant recipient. Transplantation 65(4):592–594PubMed
75.
Aris RM, Maia DM, Neuringer IP, Gott K, Kiley S, Gertis K, Handy J (1996) Post-transplantation lymphoproliferative disorder in the Epstein–Barr virus-naive lung transplant recipient. Am J Respir Crit Care Med 154(6 Pt 1):1712–1717PubMed
76.
Montone KT, Litzky LA, Wurster A, Kaiser L, Bavaria J, Kotloff R, Palevsky H, Pietra GG, Tomaszewski JE (1996) Analysis of Epstein–Barr virus-associated posttransplantation lymphoproliferative disorder after lung transplantation. Surgery 119(5):544–551PubMed
77.
Sherman LA, Chattopadhyay S (1993) The molecular basis of allorecognition. Annu Rev Immunol 11:385–402PubMed
78.
Sayegh MH, Turka LA (1998) The role of T-cell costimulatory activation pathways in transplant rejection. N Engl J Med 338(25):1813–1821PubMed
79.
Ciubotariu R, Liu Z, Colovai AI, Ho E, Itescu S, Ravalli S, Hardy MA, Cortesini R, Rose EA, Suciu-Foca N (1998) Persistent allopeptide reactivity and epitope spreading in chronic rejection of organ allografts. J Clin Invest 101(2):398–405PubMed
80.
Vella JP, Spadafora-Ferreira M, Murphy B, Alexander SI, Harmon W, Carpenter CB, Sayegh MH (1997) Indirect allorecognition of major histocompatibility complex allopeptides in human renal transplant recipients with chronic graft dysfunction. Transplantation 64(6):795–800PubMed
81.
Dinarello CA (1996) Biologic basis for interleukin-1 in disease. Blood 87(6):2095–2147PubMed
82.
Arend WP, Welgus HG, Thompson RC, Eisenberg SP (1990) Biological properties of recombinant human monocyte-derived interleukin 1 receptor antagonist. J Clin Invest 85(5):1694–1697PubMed
83.
Beutler BA (1999) The role of tumor necrosis factor in health and disease. J Rheumatol 26(Suppl 57):16–21
84.
Ostensen ME, Thiele DL, Lipsky PE (1987) Tumor necrosis factor-alpha enhances cytolytic activity of human natural killer cells. J Immunol 138(12):4185–4191PubMed
85.
Piguet PF, Collart MA, Grau GE, Kapanci Y, Vassalli P (1989) Tumor necrosis factor/cachectin plays a key role in bleomycin-induced pneumopathy and fibrosis. J Exp Med 170(3):655–663PubMed
86.
He Y, Liu W (1996) The preliminary research on the relationship between TNF- and egg-induced granuloma and hepatic fibrosis of schistosomiasis japonica. J Tongji Med Univ 16(4):205–208PubMed
87.
Krishnadasan B, Naidu BV, Byrne K, Fraga C, Verrier ED, Mulligan MS (2003) The role of proinflammatory cytokines in lung ischemia–reperfusion injury. J Thorac Cardiovasc Surg 125(2):261–272PubMed
88.
DeMeester SR, Rolfe MW, Kunkel SL, Swiderski DL, Lincoln PM, Deeb GM, Strieter RM (1993) The bimodal expression of tumor necrosis factor-alpha in association with rat lung reimplantation and allograft rejection. J Immunol 150(6):2494–2505PubMed
89.
Aris RM, Walsh S, Chalermskulrat W, Hathwar V, Neuringer IP (2002) Growth factor upregulation during obliterative bronchiolitis in the mouse model. Am J Respir Crit Care Med 166(3):417–422PubMed
90.
Smith CR, Jaramillo A, Lu KC, Higuchi T, Kaleem Z, Mohanakumar T (2001) Prevention of obliterative airway disease in HLA-A2-transgenic tracheal allografts by neutralization of tumor necrosis factor. Transplantation 72(9):1512–1518PubMed
91.
Rizzo M, SivaSai KS, Smith MA, Trulock EP, Lynch JP, Patterson GA, Mohanakumar T (2000) Increased expression of inflammatory cytokines and adhesion molecules by alveolar macrophages of human lung allograft recipients with acute rejection: decline with resolution of rejection. J Heart Lung Transplant 19(9):858–865PubMed
92.
Gately MK, Renzetti LM, Magram J, Stern AS, Adorini L, Gubler U, Presky DH (1998) The interleukin-12/interleukin-12-receptor system: role in normal and pathologic immune responses. Annu Rev Immunol 16:495–521PubMed
93.
Trinchieri G (1995) Interleukin-12: a proinflammatory cytokine with immunoregulatory functions that bridge innate resistance and antigen-specific adaptive immunity. Annu Rev Immunol 13:251–276PubMed
94.
Seder RA, Gazzinelli R, Sher A, Paul WE (1993) Interleukin 12 acts directly on CD4+ T cells to enhance priming for interferon gamma production and diminishes interleukin 4 inhibition of such priming. Proc Natl Acad Sci USA 90(21):10188–10192PubMed
95.
McKnight AJ, Zimmer GJ, Fogelman I, Wolf SF, Abbas AK (1994) Effects of IL-12 on helper T cell-dependent immune responses in vivo. J Immunol 152(5):2172–2179PubMed
96.
Marshall JD, Secrist H, DeKruyff RH, Wolf SF, Umetsu DT (1995) IL-12 inhibits the production of IL-4 and IL-10 in allergen-specific human CD4+ T lymphocytes. J Immunol 155(1):111–117PubMed
97.
Via CS, Rus V, Gately MK, Finkelman FD (1994) IL-12 stimulates the development of acute graft-versus-host disease in mice that normally would develop chronic, autoimmune graft-versus-host disease. J Immunol 153(9):4040–4047PubMed
98.
Hsieh CS, Macatonia SE, Tripp CS, Wolf SF, O'Garra A, Murphy KM (1993) Development of TH1 CD4+ T cells through IL-12 produced by Listeria-induced macrophages. Science 260(5107):547–549PubMed
99.
Oswald IP, Caspar P, Jankovic D, Wynn TA, Pearce EJ, Sher A (1994) IL-12 inhibits Th2 cytokine responses induced by eggs of Schistosoma mansoni. J Immunol 153(4):1707–1713PubMed
100.
Pearlman E, Heinzel FP, Hazlett FE Jr, Kazura JW (1995) IL-12 modulation of T helper responses to the filarial helminth, Brugia malayi. J Immunol 154(9):4658–4664PubMed
101.
Gazzinelli RT, Giese NA, Morse HC 3rd (1994) In vivo treatment with interleukin 12 protects mice from immune abnormalities observed during murine acquired immunodeficiency syndrome (MAIDS). J Exp Med 180(6):2199–2208PubMed
102.
Zhou P, Sieve MC, Bennett J, Kwon-Chung KJ, Tewari RP, Gazzinelli RT, Sher A, Seder RA (1995) IL-12 prevents mortality in mice infected with Histoplasma capsulatum through induction of IFN-gamma. J Immunol 155(2):785–795PubMed
103.
Rosenberg AS, Singer A (1992) Cellular basis of skin allograft rejection: an in vivo model of immune-mediated tissue destruction. Annu Rev Immunol 10:333–358PubMed
104.
Piccotti JR, Li K, Chan SY, Eichwald EJ, Bishop DK (1999) Interleukin-12 (IL-12)-driven alloimmune responses in vitro and in vivo: requirement for beta1 subunit of the IL-12 receptor. Transplantation 67(11):1453–1460PubMed
105.
Williamson E, Garside P, Bradley JA, More IA, Mowat AM (1997) Neutralizing IL-12 during induction of murine acute graft-versus-host disease polarizes the cytokine profile toward a Th2-type alloimmune response and confers long term protection from disease. J Immunol 159(3):1208–1215PubMed
106.
Orr DJ, Bolton EM, Bradley JA (1998) Neutralising IL-12 activity as a strategy for prolonging allograft survival and preventing graft-versus-host disease. Scott Med J 43(4):109–111PubMed
107.
Welniak LA, Blazar BR, Wiltrout RH, Anver MR, Murphy WJ (2001) Role of interleukin-12 in acute graft-versus-host disease(1). Transplant Proc 33(1–2):1752–1753PubMed
108.
Williamson E, Garside P, Bradley JA, Mowat AM (1996) IL-12 is a central mediator of acute graft-versus-host disease in mice. J Immunol 157(2):689–699PubMed
109.
Piccotti JR, Chan SY, Goodman RE, Magram J, Eichwald EJ, Bishop DK (1996) IL-12 antagonism induces T helper 2 responses, yet exacerbates cardiac allograft rejection. Evidence against a dominant protective role for T helper 2 cytokines in alloimmunity. J Immunol 157(5):1951–1957PubMed
110.
Konieczny BT, Dai Z, Elwood ET, Saleem S, Linsley PS, Baddoura FK, Larsen CP, Pearson TC, Lakkis FG (1998) IFN-gamma is critical for long-term allograft survival induced by blocking the CD28 and CD40 ligand T cell costimulation pathways. J Immunol 160(5):2059–2064PubMed
111.
Tau GZ, von der Weid T, Lu B, Cowan S, Kvatyuk M, Pernis A, Cattoretti G, Braunstein NS, Coffman RL, Rothman PB (2000) Interferon gamma signaling alters the function of T helper type 1 cells. J Exp Med 192(7):977–986PubMed
112.
Mikols CL, Yan L, Norris JY, Russell TD, Khalifah AP, Hachem RR, Chakinala MM, Yusen RD, Castro M, Kuo E, Patterson GA, Mohanakumar T, Trulock EP, Walter MJ (2006) IL-12 p80 is an innate epithelial cell effector that mediates chronic allograft dysfunction. Am J Respir Crit Care Med 174(4):461–470PubMed
113.
Meloni F, Vitulo P, Cascina A, Oggionni T, Bulgheroni A, Paschetto E, Klersy C, D'Armini AM, Fietta A, Bianco AM, Arbustini E, Vigano M (2004) Bronchoalveolar lavage cytokine profile in a cohort of lung transplant recipients: a predictive role of interleukin-12 with respect to onset of bronchiolitis obliterans syndrome. J Heart Lung Transplant 23(9):1053–1060PubMed
114.
Farrar MA, Schreiber RD (1993) The molecular cell biology of interferon-gamma and its receptor. Annu Rev Immunol 11:571–611PubMed
115.
Thierfelder WE, van Deursen JM, Yamamoto K, Tripp RA, Sarawar SR, Carson RT, Sangster MY, Vignali DA, Doherty PC, Grosveld GC, Ihle JN (1996) Requirement for Stat4 in interleukin-12-mediated responses of natural killer and T cells. Nature 382(6587):171–174PubMed
116.
Fiorentino DF, Zlotnik A, Mosmann TR, Howard M, OG A (1991) IL-10 inhibits cytokine production by activated macrophages. J Immunol 147(11):3815–3822PubMed
117.
Boehler A, Bai XH, Liu M, Cassivi S, Chamberlain D, Slutsky AS, Keshavjee S (1999) Upregulation of T-helper 1 cytokines and chemokine expression in post-transplant airway obliteration. Am J Respir Crit Care Med 159(6):1910–1917PubMed
118.
Nagano H, Mitchell RN, Taylor MK, Hasegawa S, Tilney NL, Libby P (1997) Interferon-gamma deficiency prevents coronary arteriosclerosis but not myocardial rejection in transplanted mouse hearts. J Clin Invest 100(3):550–557PubMed
119.
Raisanen-Sokolowski A, Mottram PL, Glysing-Jensen T, Satoskar A, Russell ME (1997) Heart transplants in interferon-gamma, interleukin 4, and interleukin 10 knockout mice. Recipient environment alters graft rejection. J Clin Invest 100(10):2449–2456PubMed
120.
Raisanen-Sokolowski A, Glysing-Jensen T, Russell ME (1998) Leukocyte-suppressing influences of interleukin (IL)-10 in cardiac allografts: insights from IL-10 knockout mice. Am J Pathol 153(5):1491–1500PubMed
121.
Moudgil A, Bagga A, Toyoda M, Nicolaidou E, Jordan SC, Ross D (1999) Expression of gamma-IFN mRNA in bronchoalveolar lavage fluid correlates with early acute allograft rejection in lung transplant recipients. Clin Transplant 13(2):201–207PubMed
122.
Iacono A, Dauber J, Keenan R, Spichty K, Cai J, Grgurich W, Burckart G, Smaldone G, Pham S, Ohori NP, Yousem S, Williams P, Griffith B, Zeevi A (1997) Interleukin 6 and interferon-gamma gene expression in lung transplant recipients with refractory acute cellular rejection: implications for monitoring and inhibition by treatment with aerosolized cyclosporine. Transplantation 64(2):263–269PubMed
123.
Lu KC, Jaramillo A, Lecha RL, Schuessler RB, Aloush A, Trulock EP, Mendeloff EN, Huddleston CB, Alexander Patterson G, Mohanakumar T (2002) Interleukin-6 and interferon-gamma gene polymorphisms in the development of bronchiolitis obliterans syndrome after lung transplantation. Transplantation 74(9):1297–1302PubMed
124.
Grabstein KH, Eisenman J, Shanebeck K, Rauch C, Srinivasan S, Fung V, Beers C, Richardson J, Schoenborn MA, Ahdieh M et al (1994) Cloning of a T cell growth factor that interacts with the beta chain of the interleukin-2 receptor. Science 264(5161):965–968PubMed
125.
Lodolce JP, Boone DL, Chai S, Swain RE, Dassopoulos T, Trettin S, Ma A (1998) IL-15 receptor maintains lymphoid homeostasis by supporting lymphocyte homing and proliferation. Immunity 9(5):669–676PubMed
126.
Kennedy MK, Glaccum M, Brown SN, Butz EA, Viney JL, Embers M, Matsuki N, Charrier K, Sedger L, Willis CR, Brasel K, Morrissey PJ, Stocking K, Schuh JC, Joyce S, Peschon JJ (2000) Reversible defects in natural killer and memory CD8 T cell lineages in interleukin 15-deficient mice. J Exp Med 191(5):771–780PubMed
127.
Doherty TM, Seder RA, Sher A (1996) Induction and regulation of IL-15 expression in murine macrophages. J Immunol 156(2):735–741PubMed
128.
Alleva DG, Kaser SB, Monroy MA, Fenton MJ, Beller DI (1997) IL-15 functions as a potent autocrine regulator of macrophage proinflammatory cytokine production: evidence for differential receptor subunit utilization associated with stimulation or inhibition. J Immunol 159(6):2941–2951PubMed
129.
Fehniger TA, Suzuki K, Ponnappan A, VanDeusen JB, Cooper MA, Florea SM, Freud AG, Robinson ML, Durbin J, Caligiuri MA (2001) Fatal leukemia in interleukin 15 transgenic mice follows early expansions in natural killer and memory phenotype CD8+ T cells. J Exp Med 193(2):219–231PubMed
130.
Carson WE, Giri JG, Lindemann MJ, Linett ML, Ahdieh M, Paxton R, Anderson D, Eisenmann J, Grabstein K, Caligiuri MA (1994) Interleukin (IL) 15 is a novel cytokine that activates human natural killer cells via components of the IL-2 receptor. J Exp Med 180(4):1395–1403PubMed
131.
Kanegane H, Tosato G (1996) Activation of naive and memory T cells by interleukin-15. Blood 88(1):230–235PubMed
132.
Bulfone-Paus S, Ungureanu D, Pohl T, Lindner G, Paus R, Ruckert R, Krause H, Kunzendorf U (1997) Interleukin-15 protects from lethal apoptosis in vivo. Nat Med 3(10):1124–1128PubMed
133.
Pavlakis M, Strehlau J, Lipman M, Shapiro M, Maslinski W, Strom TB (1996) Intragraft IL-15 transcripts are increased in human renal allograft rejection. Transplantation 62(4):543–545PubMed
134.
Strehlau J, Pavlakis M, Lipman M, Shapiro M, Vasconcellos L, Harmon W, Strom TB (1997) Quantitative detection of immune activation transcripts as a diagnostic tool in kidney transplantation. Proc Natl Acad Sci USA 94(2):695–700PubMed
135.
van Gelder T, Baan CC, Balk AH, Knoop CJ, Holweg CT, van der Meer P, Mochtar B, Zondervan PE, Niesters HG, Weimar W (1998) Blockade of the interleukin (IL)-2/IL-2 receptor pathway with a monoclonal anti-IL-2 receptor antibody (BT563) does not prevent the development of acute heart allograft rejection in humans. Transplantation 65(3):405–410PubMed
136.
Baan CC, Knoop CJ, van Gelder T, Holweg CT, Niesters HG, Smeets TJ, van der Ham F, Zondervan PE, Maat LP, Balk AH, Weimar W (1999) Anti-CD25 therapy reveals the redundancy of the intragraft cytokine network after clinical heart transplantation. Transplantation 67(6):870–876PubMed
137.
de Waal MR, Abrams J, Bennett B, Figdor CG, de Vries JE (1991) Interleukin 10(IL-10) inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL-10 produced by monocytes. J Exp Med 174(5):1209–1220
138.
de Waal MR, Haanen J, Spits H, Roncarolo MG, te Velde A, Figdor C, Johnson K, Kastelein R, Yssel H, de Vries JE (1991) Interleukin 10 (IL-10) and viral IL-10 strongly reduce antigen-specific human T cell proliferation by diminishing the antigen-presenting capacity of monocytes via downregulation of class II major histocompatibility complex expression. J Exp Med 174(4):915–924
139.
de Waal MR, Yssel H, Roncarolo MG, Spits H, de Vries JE (1992) Interleukin-10. Curr Opin Immunol 4(3):314–320
140.
de Waal Malefyt R, Yssel H, de Vries JE (1993) Direct effects of IL-10 on subsets of human CD4+ T cell clones and resting T cells. Specific inhibition of IL-2 production and proliferation. J Immunol 150(11):4754–4765PubMed
141.
te Velde AA, de Waal Malefijt R, Huijbens RJ, de Vries JE, Figdor CG (1992) IL-10 stimulates monocyte Fc gamma R surface expression and cytotoxic activity. Distinct regulation of antibody-dependent cellular cytotoxicity by IFN-gamma, IL-4, and IL-10. J Immunol 149(12):4048–4052
142.
Fiorentino DF, Zlotnik A, Vieira P, Mosmann TR, Howard M, Moore KW, OG A (1991) IL-10 acts on the antigen-presenting cell to inhibit cytokine production by Th1 cells. J Immunol 146(10):3444–3451PubMed
143.
Bogdan C, Vodovotz Y, Nathan C (1991) Macrophage deactivation by interleukin 10. J Exp Med 174(6):1549–1555PubMed
144.
Ralph P, Nakoinz I, Sampson-Johannes A, Fong S, Lowe D, Min HY, Lin L (1992) IL-10, T lymphocyte inhibitor of human blood cell production of IL-1 and tumor necrosis factor. J Immunol 148(3):808–814PubMed
145.
Hsu DH, de Waal MR, Fiorentino DF, Dang MN, Vieira P, de Vries J, Spits H, Mosmann TR, Moore KW (1990) Expression of interleukin-10 activity by Epstein–Barr virus protein BCRF1. Science 250(4982):830–832PubMed
146.
Hsu DH, Moore KW, Spits H (1992) Differential effects of IL-4 and IL-10 on IL-2-induced IFN-gamma synthesis and lymphokine-activated killer activity. Int Immunol 4(5):563–569PubMed
147.
Chen WF, Zlotnik A (1991) IL-10: a novel cytotoxic T cell differentiation factor. J Immunol 147(2):528–534PubMed
148.
MacNeil IA, Suda T, Moore KW, Mosmann TR, Zlotnik A (1990) IL-10, a novel growth cofactor for mature and immature T cells. J Immunol 145(12):4167–4173PubMed
149.
Hu S, Chao CC, Ehrlich LC, Sheng WS, Sutton RL, Rockswold GL, Peterson PK (1999) Inhibition of microglial cell RANTES production by IL-10 and TGF-beta. J Leukoc Biol 65(6):815–821PubMed
150.
Bejarano MT, de Waal MR, Abrams JS, Bigler M, Bacchetta R, de Vries JE, Roncarolo MG (1992) Interleukin 10 inhibits allogeneic proliferative and cytotoxic T cell responses generated in primary mixed lymphocyte cultures. Int Immunol 4(12):1389–1397PubMed
151.
Bromberg JS (1995) IL-10 immunosuppression in transplantation. Curr Opin Immunol 7(5):639–643PubMed
152.
Zuo XJ, Matsumura Y, Prehn J, Saito R, Marchevesky A, Matloff J, Jordan SC (1995) Cytokine gene expression in rejecting and tolerant rat lung allograft models: analysis by RT-PCR. Transpl Immunol 3(2):151–161PubMed
153.
Maeda H, Takata M, Takahashi S, Ogoshi S, Fujimoto S (1994) Adoptive transfer of a Th2-like cell line prolongs MHC class II antigen disparate skin allograft survival in the mouse. Int Immunol 6(6):855–862PubMed
154.
Zheng XX, Steele AW, Nickerson PW, Steurer W, Steiger J, Strom TB (1995) Administration of noncytolytic IL-10/Fc in murine models of lipopolysaccharide-induced septic shock and allogeneic islet transplantation. J Immunol 154(10):5590–5600PubMed
155.
Lee MS, Wogensen L, Shizuru J, Oldstone MB, Sarvetnick N (1994) Pancreatic islet production of murine interleukin-10 does not inhibit immune-mediated tissue destruction. J Clin Invest 93(3):1332–1338PubMed
156.
Qian S, Li W, Li Y, Fu F, Lu L, Fung JJ, Thomson AW (1996) Systemic administration of cellular interleukin-10 can exacerbate cardiac allograft rejection in mice. Transplantation 62(12):1709–1714PubMed
157.
Mulligan MS, Warner RL, McDuffie JE, Bolling SF, Sarma JV, Ward PA (2000) Regulatory role of Th-2 cytokines, IL-10 and IL-4, in cardiac allograft rejection. Exp Mol Pathol 69(1):1–9PubMed
158.
Oshima K, Sen L, Cui G, Tung T, Sacks BM, Arellano-Kruse A, Laks H (2002) Localized interleukin-10 gene transfer induces apoptosis of alloreactive T cells via FAS/FASL pathway, improves function, and prolongs survival of cardiac allograft. Transplantation 73(7):1019–1026PubMed
159.
Qin L, Chavin KD, Ding Y, Tahara H, Favaro JP, Woodward JE, Suzuki T, Robbins PD, Lotze MT, Bromberg JS (1996) Retrovirus-mediated transfer of viral IL-10 gene prolongs murine cardiac allograft survival. J Immunol 156(6):2316–2323PubMed
160.
Qin L, Ding Y, Pahud DR, Robson ND, Shaked A, Bromberg JS (1997) Adenovirus-mediated gene transfer of viral interleukin-10 inhibits the immune response to both alloantigen and adenoviral antigen. Hum Gene Ther 8(11):1365–1374PubMed
161.
de Perrot M, Fischer S, Liu M, Imai Y, Martins S, Sakiyama S, Tabata T, Bai XH, Waddell TK, Davidson BL, Keshavjee S (2003) Impact of human interleukin-10 on vector-induced inflammation and early graft function in rat lung transplantation. Am J Respir Cell Mol Biol 28(5):616–625PubMed
162.
Kozower BD, Kanaan SA, Tagawa T, Suda T, Grapperhaus K, Daddi N, Crouch EC, Doerschuk CM, Patterson GA (2002) Intramuscular gene transfer of interleukin-10 reduces neutrophil recruitment and ameliorates lung graft ischemia–reperfusion injury. Am J Transplant 2(9):837–842PubMed
163.
Martins S, de Perrot M, Imai Y, Yamane M, Quadri SM, Segall L, Dutly A, Sakiyama S, Chaparro A, Davidson BL, Waddell TK, Liu M, Keshavjee S (2004) Transbronchial administration of adenoviral-mediated interleukin-10 gene to the donor improves function in a pig lung transplant model. Gene Ther 11(24):1786–1796PubMed
164.
Pierog J, Gazdhar A, Stammberger U, Gugger M, Hyde S, Mathiesen I, Grodzki T, Schmid RA (2005) Synergistic effect of low dose cyclosporine A and human interleukin 10 overexpression on acute rejection in rat lung allotransplantation. Eur J Cardiothorac Surg 27(6):1030–1035PubMed
165.
Naidu B, Krishnadasan B, Whyte RI, Warner RL, Ward PA, Mulligan MS (2002) Regulatory role of IL-10 in experimental obliterative bronchiolitis in rats. Exp Mol Pathol 73(3):164–170PubMed
166.
Yonemitsu Y, Kitson C, Ferrari S, Farley R, Griesenbach U, Judd D, Steel R, Scheid P, Zhu J, Jeffery PK, Kato A, Hasan MK, Nagai Y, Masaki I, Fukumura M, Hasegawa M, Geddes DM, Alton EW (2000) Efficient gene transfer to airway epithelium using recombinant Sendai virus. Nat Biotechnol 18(9):970–973PubMed
167.
Shoji F, Yonemitsu Y, Okano S, Yoshino I, Nakagawa K, Nakashima Y, Hasegawa M, Sugimachi K, Sueishi K (2003) Airway-directed gene transfer of interleukin-10 using recombinant Sendai virus effectively prevents post-transplant fibrous airway obliteration in mice. Gene Ther 10(3):213–218PubMed
168.
Salgar SK, Yang D, Ruiz P, Miller J, Tzakis AG (2004) Viral interleukin-10-engineered autologous hematopoietic stem cell therapy: a novel gene therapy approach to prevent graft rejection. Hum Gene Ther 15(2):131–144PubMed
169.
Zheng HX, Burckart GJ, McCurry K, Webber S, Ristich J, Iacono A, Dauber J, McDade K, Grgurich W, Zaldonis D, Pillage G, Griffith BP, Zeevi A (2004) Interleukin-10 production genotype protects against acute persistent rejection after lung transplantation. J Heart Lung Transplant 23(5):541–546PubMed
170.
Keane MP, Gomperts BN, Weigt S, Xue YY, Burdick MD, Nakamura H, Zisman DA, Ardehali A, Saggar R, Lynch JP 3rd, Hogaboam C, Kunkel SL, Lukacs NW, Ross DJ, Grusby MJ, Strieter RM, Belperio JA (2007) IL-13 is pivotal in the fibro-obliterative process of bronchiolitis obliterans syndrome. J Immunol 178(1):511–519PubMed
171.
Lama VN, Harada H, Badri LN, Flint A, Hogaboam CM, McKenzie A, Martinez FJ, Toews GB, Moore BB, Pinsky DJ (2006) Obligatory role for interleukin-13 in obstructive lesion development in airway allografts. Am J Pathol 169(1):47–60PubMed
172.
Kishimoto T (1992) Interleukin-6 and its receptor in autoimmunity. J Autoimmun 5(Suppl A):123–132PubMed
173.
Hirano T, Matsuda T, Turner M, Miyasaka N, Buchan G, Tang B, Sato K, Shimizu M, Maini R, Feldmann M et al (1988) Excessive production of interleukin 6/B cell stimulatory factor-2 in rheumatoid arthritis. Eur J Immunol 18(11):1797–1801PubMed
174.
Taga T, Kishimoto T (1997) Gp130 and the interleukin-6 family of cytokines. Annu Rev Immunol 15:797–819PubMed
175.
Shahar I, Fireman E, Topilsky M, Grief J, Kivity S, Spirer Z, Ben Efraim S (1996) Effect of IL-6 on alveolar fibroblast proliferation in interstitial lung diseases. Clin Immunol Immunopathol 79(3):244–251PubMed
176.
Horii Y, Muraguchi A, Iwano M, Matsuda T, Hirayama T, Yamada H, Fujii Y, Dohi K, Ishikawa H, Ohmoto Y et al (1989) Involvement of IL-6 in mesangial proliferative glomerulonephritis. J Immunol 143(12):3949–3955PubMed
177.
Rolfe MW, Kunkel S, Lincoln P, Deeb M, Lupinetti F, Strieter R (1993) Lung allograft rejection: role of tumor necrosis factor-alpha and interleukin-6. Chest 103(2 Suppl):133SPubMed
178.
Farivar AS, Merry HE, Fica-Delgado MJ, McCourtie AS, Mackinnon-Patterson BC, Mulligan MS (2006) Interleukin-6 regulation of direct lung ischemia reperfusion injury. Ann Thorac Surg 82(2):472–478PubMed
179.
Scholma J, Slebos DJ, Boezen HM, van den Berg JW, van der Bij W, de Boer WJ, Koeter GH, Timens W, Kauffman HF, Postma DS (2000) Eosinophilic granulocytes and interleukin-6 level in bronchoalveolar lavage fluid are associated with the development of obliterative bronchiolitis after lung transplantation. Am J Respir Crit Care Med 162(6):2221–2225PubMed
180.
Penttinen RP, Kobayashi S, Bornstein P (1988) Transforming growth factor beta increases mRNA for matrix proteins both in the presence and in the absence of changes in mRNA stability. Proc Natl Acad Sci USA 85(4):1105–1108PubMed
181.
Roberts AB, Sporn MB, Assoian RK, Smith JM, Roche NS, Wakefield LM, Heine UI, Liotta LA, Falanga V, Kehrl JH et al (1986) Transforming growth factor type beta: rapid induction of fibrosis and angiogenesis in vivo and stimulation of collagen formation in vitro. Proc Natl Acad Sci USA 83(12):4167–4171PubMed
182.
Mora BN, Boasquevisque CH, Boglione M, Ritter JM, Scheule RK, Yew NS, Debruyne L, Qin L, Bromberg JS, Patterson GA (2000) Transforming growth factor-beta1 gene transfer ameliorates acute lung allograft rejection. J Thorac Cardiovasc Surg 119(5):913–920PubMed
183.
Qin L, Chavin KD, Ding Y, Woodward JE, Favaro JP, Lin J, Bromberg JS (1994) Gene transfer for transplantation. Prolongation of allograft survival with transforming growth factor-beta 1. Ann Surg 220(4):508–518, discussion 518–509PubMed
184.
Yasufuku K, Heidler KM, O'Donnell PW, Smith GN Jr, Cummings OW, Foresman BH, Fujisawa T, Wilkes DS (2001) Oral tolerance induction by type V collagen downregulates lung allograft rejection. Am J Respir Cell Mol Biol 25(1):26–34PubMed
185.
Liu M, Suga M, Maclean AA, St George JA, Souza DW, Keshavjee S (2002) Soluble transforming growth factor-beta type III receptor gene transfection inhibits fibrous airway obliteration in a rat model of bronchiolitis obliterans. Am J Respir Crit Care Med 165(3):419–423PubMed
186.
Massague J, Wotton D (2000) Transcriptional control by the TGF-beta/Smad signaling system. EMBO J 19(8):1745–1754PubMed
187.
Elssner A, Jaumann F, Dobmann S, Behr J, Schwaiblmair M, Reichenspurner H, Furst H, Briegel J, Vogelmeier C (2000) Elevated levels of interleukin-8 and transforming growth factor-beta in bronchoalveolar lavage fluid from patients with bronchiolitis obliterans syndrome: proinflammatory role of bronchial epithelial cells. Munich Lung Transplant Group. Transplantation 70(2):362–367PubMed
188.
El-Gamel A, Sim E, Hasleton P, Hutchinson J, Yonan N, Egan J, Campbell C, Rahman A, Sheldon S, Deiraniya A, Hutchinson IV (1999) Transforming growth factor beta (TGF-beta) and obliterative bronchiolitis following pulmonary transplantation. J Heart Lung Transplant 18(9):828–837PubMed
189.
Charpin JM, Valcke J, Kettaneh L, Epardeau B, Stern M, Israel-Biet D (1998) Peaks of transforming growth factor-beta mRNA in alveolar cells of lung transplant recipients as an early marker of chronic rejection. Transplantation 65(5):752–755PubMed
190.
Shin HC, Benbernou N, Esnault S, Guenounou M (1999) Expression of IL-17 in human memory CD45RO+ T lymphocytes and its regulation by protein kinase A pathway. Cytokine 11(4):257–266PubMed
191.
Rouvier E, Luciani MF, Mattei MG, Denizot F, Golstein P (1993) CTLA-8, cloned from an activated T cell, bearing AU-rich messenger RNA instability sequences, and homologous to a herpesvirus saimiri gene. J Immunol 150(12):5445–5456PubMed
192.
Infante-Duarte C, Horton HF, Byrne MC, Kamradt T (2000) Microbial lipopeptides induce the production of IL-17 in Th cells. J Immunol 165(11):6107–6115PubMed
193.
Kennedy J, Rossi DL, Zurawski SM, Vega F Jr, Kastelein RA, Wagner JL, Hannum CH, Zlotnik A (1996) Mouse IL-17: a cytokine preferentially expressed by alpha beta TCR+ CD4-CD8-T cells. J Interferon Cytokine Res 16(8):611–617PubMed
194.
Jovanovic DV, Di Battista JA, Martel-Pelletier J, Jolicoeur FC, He Y, Zhang M, Mineau F, Pelletier JP (1998) IL-17 stimulates the production and expression of proinflammatory cytokines, IL-beta and TNF-alpha, by human macrophages. J Immunol 160(7):3513–3521PubMed
195.
Aggarwal S, Gurney AL (2002) IL-17: prototype member of an emerging cytokine family. J Leukoc Biol 71(1):1–8PubMed
196.
Moseley TA, Haudenschild DR, Rose L, Reddi AH (2003) Interleukin-17 family and IL-17 receptors. Cytokine Growth Factor Rev 14(2):155–174PubMed
197.
Antonysamy MA, Fanslow WC, Fu F, Li W, Qian S, Troutt AB, Thomson AW (1999) Evidence for a role of IL-17 in organ allograft rejection: IL-17 promotes the functional differentiation of dendritic cell progenitors. J Immunol 162(1):577–584PubMed
198.
Burlingham WJ, Love RB, Jankowska-Gan E, Haynes LD, Xu Q, Bobadilla JL, Meyer KC, Hayney MS, Braun RK, Greenspan DS, Gopalakrishnan B, Cai J, Brand DD, Yoshida S, Cummings OW, Wilkes DS (2007) IL-17-dependent cellular immunity to collagen type V predisposes to obliterative bronchiolitis in human lung transplants. J Clin Invest 117(11):3498–3506. doi:10.​1172/​JCI28031 PubMed
199.
Vanaudenaerde BM, De Vleeschauwer SI, Vos R, Meyts I, Bullens DM, Reynders V, Wuyts WA, Van Raemdonck DE, Dupont LJ, Verleden GM (2008) The role of the IL23/IL17 axis in bronchiolitis obliterans syndrome after lung transplantation. Am J Transplant 8(9):1911–1920. doi:10.​1111/​j.​1600-6143.​2008.​02321.​x PubMed
200.
Cao H, Lan Q, Shi Q, Zhou X, Liu G, Liu J, Tang G, Qiu C, Xu J, Fan H, Liu Z (2010) Anti-IL-23 antibody blockade of IL-23/IL-17 pathway attenuates airway obliteration in rat orthotopic tracheal transplantation. Int Immunopharmacol. doi:10.​1016/​j.​intimp.​2010.​11.​007
201.
202.
Luster AD (1998) Mechanisms of disease: chemokines—chemotactic cytokines that mediate inflammation. N Engl J Med 338(7):436–445PubMed
203.
Strieter RM, Kunkel SL (1997) Chemokines and the lung. In: Crystal R, West J, Weibel E, Barnes P (eds) Lung: scientific foundations, 2nd edn. Raven, New York, pp 155–186
204.
Bleul CC, Fuhlbrigge RC, Casasnovas JM, Aiuti A, Springer TA (1996) A highly efficacious lymphocyte chemoattractant, stromal cell-derived factor 1 (SDF-1). J Exp Med 184(3):1101–1109 (see comments)PubMed
205.
Loetscher M, Gerber B, Loetscher P, Jones SA, Piali L, Clark-Lewis I, Baggiolini M, Moser B (1996) Chemokine receptor specific for IP10 and Mig: structure, function, and expression in activated T-lymphocytes. J Exp Med 184(3):963–969 (see comments)PubMed
206.
Keane MP, Belperio JA, Arenberg DA, Burdick MD, Xu ZJ, Xue YY, Strieter RM (1999) IFN-gamma-inducible protein-10 attenuates bleomycin-induced pulmonary fibrosis via inhibition of angiogenesis. J Immunol 163(10):5686–5692 (in process citation)PubMed
207.
Keane MP, Belperio JA, Moore TA, Moore BB, Arenberg DA, Smith RE, Burdick MD, Kunkel SL, Strieter RM (1999) Neutralization of the CXC chemokine, macrophage inflammatory protein-2, attenuates bleomycin-induced pulmonary fibrosis. J Immunol 162(9):5511–5518PubMed
208.
Moore BB, Arenberg DA, Addison CL, Keane MP, Strieter RM (1998) Tumor angiogenesis is regulated by CXC chemokines. J Lab Clin Med 132(2):97–103PubMed
209.
Baggiolini M, Dewald B, Moser B (1997) Human chemokines: an update. Annu Rev Immunol 15:675–705PubMed
210.
Robinson LA, Nataraj C, Thomas DW, Howell DN, Griffiths R, Bautch V, Patel DD, Feng L, Coffman TM (2000) A role for fractalkine and its receptor (CX3CR1) in cardiac allograft rejection. J Immunol 165(11):6067–6072PubMed
211.
Fong AM, Robinson LA, Steeber DA, Tedder TF, Yoshie O, Imai T, Patel DD (1998) Fractalkine and CX3CR1 mediate a novel mechanism of leukocyte capture, firm adhesion, and activation under physiologic flow. J Exp Med 188(8):1413–1419PubMed
212.
Pan Y, Lloyd C, Zhou H, Dolich S, Deeds J, Gonzalo JA, Vath J, Gosselin M, Ma J, Dussault B, Woolf E, Alperin G, Culpepper J, Gutierrez-Ramos JC, Gearing D (1997) Neurotactin, a membrane-anchored chemokine upregulated in brain inflammation. Nature 387(6633):611–617 (published erratum appears in Nature 1997 Sep 4;389(6646):100)PubMed
213.
Bazan JF, Bacon KB, Hardiman G, Wang W, Soo K, Rossi D, Greaves DR, Zlotnik A, Schall TJ (1997) A new class of membrane-bound chemokine with a CX3C motif. Nature 385(6617):640–644PubMed
214.
Murphy PM, Baggiolini M, Charo IF, Hebert CA, Horuk R, Matsushima K, Miller LH, Oppenheim JJ, Power CA (2000) International union of pharmacology. XXII. Nomenclature for chemokine receptors. Pharmacol Rev 52(1):145–176PubMed
215.
Segerer S, Nelson PJ, Schlondorff D (2000) Chemokines, chemokine receptors, and renal disease: from basic science to pathophysiologic and therapeutic studies. J Am Soc Nephrol 11(1):152–176PubMed
216.
Monti G, Magnan A, Fattal M, Rain B, Humbert M, Mege JL, Noirclerc M, Dartevelle P, Cerrina J, Simonneau G, Galanaud P, Emilie D (1996) Intrapulmonary production of RANTES during rejection and CMV pneumonitis after lung transplantation. Transplantation 61(12):1757–1762PubMed
217.
Belperio JA, Burdick MD, Keane MP, Xue YY, Lynch JP 3rd, Daugherty BL, Kunkel SL, Strieter RM (2000) The role of the CC chemokine, RANTES, in acute lung allograft rejection. J Immunol 165(1):461–472PubMed
218.
Suga M, Maclean AA, Keshavjee S, Fischer S, Moreira JM, Liu M (2000) RANTES plays an important role in the evolution of allograft transplant-induced fibrous airway obliteration. Am J Respir Crit Care Med 162(5):1940–1948PubMed
219.
Krishnadasan B, Farivar AS, Naidu BV, Woolley SM, Byrne K, Fraga CH, Mulligan MS (2004) Beta-chemokine function in experimental lung ischemia–reperfusion injury. Ann Thorac Surg 77(3):1056–1062PubMed
220.
Belperio JA, Keane MP, Burdick MD, Lynch JP 3rd, Xue YY, Berlin A, Ross DJ, Kunkel SL, Charo IF, Strieter RM (2001) Critical role for the chemokine MCP-1/CCR2 in the pathogenesis of bronchiolitis obliterans syndrome. J Clin Invest 108(4):547–556PubMed
221.
Farivar AS, Krishnadasan B, Naidu BV, Woolley SM, Mulligan MS (2003) The role of the beta chemokines in experimental obliterative bronchiolitis. Exp Mol Pathol 75(3):210–216PubMed
222.
Gelman AE, Okazaki M, Sugimoto S, Li W, Kornfeld CG, Lai J, Richardson SB, Kreisel FH, Huang HJ, Tietjens JR, Zinselmeyer BH, Patterson GA, Miller MJ, Krupnick AS, Kreisel D (2010) CCR2 regulates monocyte recruitment as well as CD4 T1 allorecognition after lung transplantation. Am J Transplant 10(5):1189–1199. doi:10.​1111/​j.​1600-6143.​2010.​03101.​x PubMed
223.
Hori S, Nomura T, Sakaguchi S (2003) Control of regulatory T cell development by the transcription factor Foxp3. Science 299(5609):1057–1061PubMed
224.
Lee I, Wang L, Wells AD, Dorf ME, Ozkaynak E, Hancock WW (2005) Recruitment of Foxp3+ T regulatory cells mediating allograft tolerance depends on the CCR4 chemokine receptor. J Exp Med 201(7):1037–1044PubMed
225.
Alferink J, Lieberam I, Reindl W, Behrens A, Weiss S, Huser N, Gerauer K, Ross R, Reske-Kunz AB, Ahmad-Nejad P, Wagner H, Forster I (2003) Compartmentalized production of CCL17 in vivo: strong inducibility in peripheral dendritic cells contrasts selective absence from the spleen. J Exp Med 197(5):585–599PubMed
226.
Forster R, Schubel A, Breitfeld D, Kremmer E, Renner-Muller I, Wolf E, Lipp M (1999) CCR7 coordinates the primary immune response by establishing functional microenvironments in secondary lymphoid organs. Cell 99(1):23–33PubMed
227.
Sallusto F, Mackay CR, Lanzavecchia A (2000) The role of chemokine receptors in primary, effector, and memory immune responses. Annu Rev Immunol 18:593–620PubMed
228.
Cyster JG (1999) Chemokines and cell migration in secondary lymphoid organs. Science 286(5447):2098–2102PubMed
229.
Gregson AL, Hoji A, Saggar R, Ross DJ, Kubak BM, Jamieson BD, Weigt SS, Lynch JP 3rd, Ardehali A, Belperio JA, Yang OO (2008) Bronchoalveolar immunologic profile of acute human lung transplant allograft rejection. Transplantation 85(7):1056–1059. doi:10.​1097/​TP.​0b013e318169bd85​ PubMed
230.
Gregson AL, Hoji A, Palchevskiy V, Hu S, Weigt SS, Liao E, Derhovanessian A, Saggar R, Song S, Elashoff R, Yang OO, Belperio JA (2010) Protection against bronchiolitis obliterans syndrome is associated with allograft CCR7+CD45RA− T regulatory cells. PLoS One 5(6):e11354. doi:10.​1371/​journal.​pone.​0011354 PubMed
231.
Meloni F, Solari N, Miserere S, Morosini M, Cascina A, Klersy C, Arbustini E, Pellegrini C, Vigano M, Fietta AM (2008) Chemokine redundancy in BOS pathogenesis. A possible role also for the CC chemokines: MIP3-beta, MIP3-alpha, MDC and their specific receptors. Transpl Immunol 18(3):275–280. doi:10.​1016/​j.​trim.​2007.​08.​004 PubMed
232.
Imai T, Hieshima K, Haskell C, Baba M, Nagira M, Nishimura M, Kakizaki M, Takagi S, Nomiyama H, Schall TJ, Yoshie O (1997) Identification and molecular characterization of fractalkine receptor CX3CR1, which mediates both leukocyte migration and adhesion. Cell 91(4):521–530PubMed
233.
Combadiere C, Gao J, Tiffany HL, Murphy PM (1998) Gene cloning, RNA distribution, and functional expression of mCX3CR1, a mouse chemotactic receptor for the CX3C chemokine fractalkine. Biochem Biophys Res Commun 253(3):728–732PubMed
234.
Maciejewski-Lenoir D, Chen S, Feng L, Maki R, Bacon KB (1999) Characterization of fractalkine in rat brain cells: migratory and activation signals for CX3CR-1-expressing microglia. J Immunol 163(3):1628–1635PubMed
235.
Harrison JK, Jiang Y, Chen S, Xia Y, Maciejewski D, McNamara RK, Streit WJ, Salafranca MN, Adhikari S, Thompson DA, Botti P, Bacon KB, Feng L (1998) Role for neuronally derived fractalkine in mediating interactions between neurons and CX3CR1-expressing microglia. Proc Natl Acad Sci USA 95(18):10896–10901PubMed
236.
Feng L, Chen S, Garcia GE, Xia Y, Siani MA, Botti P, Wilson CB, Harrison JK, Bacon KB (1999) Prevention of crescentic glomerulonephritis by immunoneutralization of the fractalkine receptor CX3CR1 rapid communication. Kidney Int 56(2):612–620PubMed
237.
Haskell CA, Hancock WW, Salant DJ, Gao W, Csizmadia V, Peters W, Faia K, Fituri O, Rottman JB, Charo IF (2001) Targeted deletion of CX(3)CR1 reveals a role for fractalkine in cardiac allograft rejection. J Clin Invest 108(5):679–688PubMed
238.
Taub DD, Lloyd AR, Conlon K, Wang JM, Ortaldo JR, Harada A, Matsushima K, Kelvin DJ, Oppenheim JJ (1993) Recombinant human interferon-inducible protein 10 is a chemoattractant for human monocytes and T lymphocytes and promotes T cell adhesion to endothelial cells. J Exp Med 177(6):1809–1814PubMed
239.
Sallusto F, Lenig D, Mackay CR, Lanzavecchia A (1998) Flexible programs of chemokine receptor expression on human polarized T helper 1 and 2 lymphocytes. J Exp Med 187(6):875–883PubMed
240.
Bonecchi R, Bianchi G, Bordignon PP, D'Ambrosio D, Lang R, Borsatti A, Sozzani S, Allavena P, Gray PA, Mantovani A, Sinigaglia F (1998) Differential expression of chemokine receptors and chemotactic responsiveness of type 1 T helper cells (Th1s) and Th2s. J Exp Med 187(1):129–134PubMed
241.
Maghazachi AA, Skalhegg BS, Rolstad B, Al-Aoukaty A (1997) Interferon-inducible protein-10 and lymphotactin induce the chemotaxis and mobilization of intracellular calcium in natural killer cells through pertussis toxin-sensitive and -insensitive heterotrimeric G-proteins. FASEB J 11(10):765–774PubMed
242.
Liao F, Rabin RL, Yannelli JR, Koniaris LG, Vanguri P, Farber JM (1995) Human Mig chemokine: biochemical and functional characterization. J Exp Med 182(5):1301–1314PubMed
243.
Rabin RL, Park MK, Liao F, Swofford R, Stephany D, Farber JM (1999) Chemokine receptor responses on T cells are achieved through regulation of both receptor expression and signaling. J Immunol 162(7):3840–3850PubMed
244.
Qin S, Rottman JB, Myers P, Kassam N, Weinblatt M, Loetscher M, Koch AE, Moser B, Mackay CR (1998) The chemokine receptors CXCR3 and CCR5 mark subsets of T cells associated with certain inflammatory reactions. J Clin Invest 101(4):746–754PubMed
245.
Piali L, Weber C, LaRosa G, Mackay CR, Springer TA, Clark-Lewis I, Moser B (1998) The chemokine receptor CXCR3 mediates rapid and shear-resistant adhesion-induction of effector T lymphocytes by the chemokines IP10 and Mig. Eur J Immunol 28(3):961–972PubMed
246.
Zhai Y, Shen XD, Hancock WW, Gao F, Qiao B, Lassman C, Belperio JA, Strieter RM, Busuttil RW, Kupiec-Weglinski JW (2006) CXCR3+CD4+ T cells mediate innate immune function in the pathophysiology of liver ischemia/reperfusion injury. J Immunol 176(10):6313–6322PubMed
247.
Zhao DX, Hu Y, Miller GG, Luster AD, Mitchell RN, Libby P (2002) Differential expression of the IFN-gamma-inducible CXCR3-binding chemokines, IFN-inducible protein 10, monokine induced by IFN, and IFN-inducible T cell alpha chemoattractant in human cardiac allografts: association with cardiac allograft vasculopathy and acute rejection. J Immunol 169(3):1556–1560PubMed
248.
Melter M, Exeni A, Reinders ME, Fang JC, McMahon G, Ganz P, Hancock WW, Briscoe DM (2001) Expression of the chemokine receptor CXCR3 and its ligand IP-10 during human cardiac allograft rejection. Circulation 104(21):2558–2564PubMed
249.
Kao J, Kobashigawa J, Fishbein MC, MacLellan WR, Burdick MD, Belperio JA, Strieter RM (2003) Elevated serum levels of the CXCR3 chemokine ITAC are associated with the development of transplant coronary artery disease. Circulation 107(15):1958–1961PubMed
250.
Hancock WW, Lu B, Gao W, Csizmadia V, Faia K, King JA, Smiley ST, Ling M, Gerard NP, Gerard C (2000) Requirement of the chemokine receptor CXCR3 for acute allograft rejection. J Exp Med 192(10):1515–1520PubMed
251.
Hancock WW, Gao W, Csizmadia V, Faia KL, Shemmeri N, Luster AD (2001) Donor-derived IP-10 initiates development of acute allograft rejection. J Exp Med 193(8):975–980PubMed
252.
Miura M, Morita K, Kobayashi H, Hamilton TA, Burdick MD, Strieter RM, Fairchild RL (2001) Monokine induced by IFN-gamma is a dominant factor directing T cells into murine cardiac allografts during acute rejection. J Immunol 167(6):3494–3504PubMed
253.
Baker MS, Chen X, Rotramel AR, Nelson JJ, Lu B, Gerard C, Kanwar Y, Kaufman DB (2003) Genetic deletion of chemokine receptor CXCR3 or antibody blockade of its ligand IP-10 modulates posttransplantation graft-site lymphocytic infiltrates and prolongs functional graft survival in pancreatic islet allograft recipients. Surgery 134(2):126–133PubMed
254.
Agostini C, Calabrese F, Rea F, Facco M, Tosoni A, Loy M, Binotto G, Valente M, Trentin L, Semenzato G (2001) Cxcr3 and its ligand CXCL10 are expressed by inflammatory cells infiltrating lung allografts and mediate chemotaxis of T cells at sites of rejection. Am J Pathol 158(5):1703–1711PubMed
255.
Belperio JA, Keane MP, Burdick MD, Lynch JP 3rd, Xue YY, Li K, Ross DJ, Strieter RM (2002) Critical role for CXCR3 chemokine biology in the pathogenesis of bronchiolitis obliterans syndrome. J Immunol 169(2):1037–1049PubMed
256.
Medoff BD, Wain JC, Seung E, Jackobek R, Means TK, Ginns LC, Farber JM, Luster AD (2006) CXCR3 and its ligands in a murine model of obliterative bronchiolitis: regulation and function. J Immunol 176(11):7087–7095PubMed
257.
Ebert LM, Schaerli P, Moser B (2005) Chemokine-mediated control of T cell traffic in lymphoid and peripheral tissues. Mol Immunol 42(7):799–809PubMed
258.
Lee BP, Chen W, Shi H, Der SD, Forster R, Zhang L (2006) CXCR5/CXCL13 interaction is important for double-negative regulatory T cell homing to cardiac allografts. J Immunol 176(9):5276–5283PubMed
259.
Belperio JA, Keane MP, Arenberg DA, Addison CL, Ehlert JE, Burdick MD, Strieter RM (2000) CXC chemokines in angiogenesis. J Leukoc Biol 68(1):1–8PubMed
260.
Belperio JA, Keane MP, Burdick MD, Gomperts B, Xue YY, Hong K, Mestas J, Ardehali A, Mehrad B, Saggar R, Lynch JP, Ross DJ, Strieter RM (2005) Role of CXCR2/CXCR2 ligands in vascular remodeling during bronchiolitis obliterans syndrome. J Clin Invest 115(5):1150–1162PubMed
261.
Fisher AJ, Donnelly SC, Hirani N, Haslett C, Strieter RM, Dark JH, Corris PA (2001) Elevated levels of interleukin-8 in donor lungs is associated with early graft failure after lung transplantation. Am J Respir Crit Care Med 163(1):259–265PubMed
262.
De Perrot M, Sekine Y, Fischer S, Waddell TK, McRae K, Liu M, Wigle DA, Keshavjee S (2002) Interleukin-8 release during early reperfusion predicts graft function in human lung transplantation. Am J Respir Crit Care Med 165(2):211–215PubMed
263.
Riise GC, Williams A, Kjellstrom C, Schersten H, Andersson BA, Kelly FJ (1998) Bronchiolitis obliterans syndrome in lung transplant recipients is associated with increased neutrophil activity and decreased antioxidant status in the lung. Eur Respir J 12(1):82–88PubMed
264.
Riise GC, Andersson BA, Kjellstrom C, Martensson G, Nilsson FN, Ryd W, Schersten H (1999) Persistent high BAL fluid granulocyte activation marker levels as early indicators of bronchiolitis obliterans after lung transplant. Eur Respir J 14(5):1123–1130PubMed
265.
Zheng L, Walters EH, Ward C, Wang N, Orsida B, Whitford H, Williams TJ, Kotsimbos T, Snell GI (2000) Airway neutrophilia in stable and bronchiolitis obliterans syndrome patients following lung transplantation. Thorax 55(1):53–59PubMed
266.
Elssner A, Vogelmeier C (2001) The role of neutrophils in the pathogenesis of obliterative bronchiolitis after lung transplantation. Transpl Infect Dis 3(3):168–176PubMed
267.
DiGiovine B, Lynch JP 3rd, Martinez FJ, Flint A, Whyte RI, Iannettoni MD, Arenberg DA, Burdick MD, Glass MC, Wilke CA, Morris SB, Kunkel SL, Strieter RM (1996) Bronchoalveolar lavage neutrophilia is associated with obliterative bronchiolitis after lung transplantation: role of IL-8. J Immunol 157(9):4194–4202PubMed
268.
Bhorade SM, Chen H, Molinero L, Liao C, Garrity ER, Vigneswaran WT, Shilling R, Sperling A, Chong A, Alegre ML (2010) Decreased percentage of CD4+FoxP3+ cells in bronchoalveolar lavage from lung transplant recipients correlates with development of bronchiolitis obliterans syndrome. Transplantation 90(5):540–546PubMed
269.
Macpherson AJ, Harris NL (2004) Interactions between commensal intestinal bacteria and the immune system. Nat Rev Immunol 4(6):478–485. doi:10.​1038/​nri1373 PubMed
270.
Podolsky DK (2002) The current future understanding of inflammatory bowel disease. Best Pract Res Clin Gastroenterol 16(6):933–943PubMed
271.
272.
273.
Schmechel S, Konrad A, Diegelmann J, Glas J, Wetzke M, Paschos E, Lohse P, Goke B, Brand S (2008) Linking genetic susceptibility to Crohn's disease with Th17 cell function: IL-22 serum levels are increased in Crohn's disease and correlate with disease activity and IL23R genotype status. Inflamm Bowel Dis 14(2):204–212. doi:10.​1002/​ibd.​20315 PubMed
274.
Kobayashi T, Okamoto S, Hisamatsu T, Kamada N, Chinen H, Saito R, Kitazume MT, Nakazawa A, Sugita A, Koganei K, Isobe K, Hibi T (2008) IL23 differentially regulates the Th1/Th17 balance in ulcerative colitis and Crohn's disease. Gut 57(12):1682–1689. doi:10.​1136/​gut.​2007.​135053 PubMed
275.
Fontenot JD, Rudensky AY (2005) A well adapted regulatory contrivance: regulatory T cell development and the forkhead family transcription factor Foxp3. Nat Immunol 6(4):331–337. doi:10.​1038/​ni1179 PubMed
276.
Ivanov II, Frutos Rde L, Manel N, Yoshinaga K, Rifkin DB, Sartor RB, Finlay BB, Littman DR (2008) Specific microbiota direct the differentiation of IL-17-producing T-helper cells in the mucosa of the small intestine. Cell Host Microbe 4(4):337–349. doi:10.​1016/​j.​chom.​2008.​09.​009 PubMed
277.
Di Giacinto C, Marinaro M, Sanchez M, Strober W, Boirivant M (2005) Probiotics ameliorate recurrent Th1-mediated murine colitis by inducing IL-10 and IL-10-dependent TGF-beta-bearing regulatory cells. J Immunol 174(6):3237–3246PubMed
278.
O'Mahony C, Scully P, O'Mahony D, Murphy S, O'Brien F, Lyons A, Sherlock G, MacSharry J, Kiely B, Shanahan F, O'Mahony L (2008) Commensal-induced regulatory T cells mediate protection against pathogen-stimulated NF-kappaB activation. PLoS Pathog 4(8):e1000112. doi:10.​1371/​journal.​ppat.​1000112 PubMed
279.
Hilty M, Burke C, Pedro H, Cardenas P, Bush A, Bossley C, Davies J, Ervine A, Poulter L, Pachter L, Moffatt MF, Cookson WO (2010) Disordered microbial communities in asthmatic airways. PLoS One 5(1):e8578. doi:10.​1371/​journal.​pone.​0008578 PubMed
280.
Huang YJ, Kim E, Cox MJ, Brodie EL, Brown R, Wiener-Kronish JP, Lynch SV (2010) A persistent and diverse airway microbiota present during chronic obstructive pulmonary disease exacerbations. OMICS 14(1):9–59. doi:10.​1089/​omi.​2009.​0100 PubMed
281.
Bittar F, Richet H, Dubus JC, Reynaud-Gaubert M, Stremler N, Sarles J, Raoult D, Rolain JM (2008) Molecular detection of multiple emerging pathogens in sputa from cystic fibrosis patients. PLoS ONE 3(8):e2908. doi:10.​1371/​journal.​pone.​0002908 PubMed
282.
Armougom F, Bittar F, Stremler N, Rolain JM, Robert C, Dubus JC, Sarles J, Raoult D, La Scola B (2009) Microbial diversity in the sputum of a cystic fibrosis patient studied with 16S rDNA pyrosequencing. Eur J Clin Microbiol Infect Dis 28(9):1151–1154. doi:10.​1007/​s10096-009-0749-x PubMed
283.
Harris JK, De Groote MA, Sagel SD, Zemanick ET, Kapsner R, Penvari C, Kaess H, Deterding RR, Accurso FJ, Pace NR (2007) Molecular identification of bacteria in bronchoalveolar lavage fluid from children with cystic fibrosis. Proc Natl Acad Sci USA 104(51):20529–20533. doi:10.​1073/​pnas.​0709804104 PubMed
284.
285.
Round JL, Mazmanian SK (2009) The gut microbiota shapes intestinal immune responses during health and disease. Nat Rev Immunol 9(5):313–323PubMed
Metadaten
Titel
Lung transplantation: infection, inflammation, and the microbiome
verfasst von
Takeshi Nakajima
Vyachesav Palchevsky
David L. Perkins
John A. Belperio
Patricia W. Finn
Publikationsdatum
01.03.2011
Verlag
Springer-Verlag
Erschienen in
Seminars in Immunopathology / Ausgabe 2/2011
Print ISSN: 1863-2297
Elektronische ISSN: 1863-2300
DOI
https://doi.org/10.1007/s00281-011-0249-9

Weitere Artikel der Ausgabe 2/2011

Seminars in Immunopathology 2/2011 Zur Ausgabe

Review

Advances of genomic science and systems biology in renal transplantation: a review

Review

Loss of tolerance to self after transplant

Review

Inflammation and transplantation tolerance

Review

Role of Th17 cells and IL-17 in lung transplant rejection

Review

Steroids in kidney transplant patients

Review

Regulatory T cells in lung transplantation—an emerging concept

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise